至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity

Vaccine. 2021-07; 
Anne-Catherine Fluckiger, Barthelemy Ontsouka, Jasminka Bozic, Abebaw Diress, Tanvir Ahmed, Tamara Berthoud, Anh Tran, Diane Duque, Mingmin Liao, Michael McCluskie, Francisco Diaz-Mitoma, David E Anderson, Catalina Soare
Products/Services Used Details Operation
PCR Cloning and Subcloning … All sequences were codon optimized for expression in human cells prior to synthesis and subcloning into a proprietary modified phCMV plasmid at Genscript (Piscataway, NJ). eVLPs were produced by transient polyethylenimine transfection in proprietary HEK-293SF-3F6 GMP … Get A Quote

摘要

We evaluated enveloped virus-like particles (eVLPs) expressing various forms of the Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein and several adjuvants in an effort to identify a highly potent Coronavirus disease 2019 (COVID-19) vaccine candidate. eVLPs expressing a modified prefusion form of SARS-CoV-2 spike protein were selected as they induced high antibody binding titers and neutralizing activity after a single injection in mice. Formulation of SARS-CoV-2 S eVLPs with aluminum phosphate resulted in balanced induction of IgG2 and IgG1 isotypes and antibody binding and neutralization titers were undiminished for more than 3 months after a single immunization. A single dose of thi... More

关键词

Immunogenicity, Neutralizing antibodies, SARS-COV-2, Vaccine, Virus-like-particles